Eli Lilly and Co (LLY) : Diam Ltd. scooped up 119,584 additional shares in Eli Lilly and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 3, 2016. The investment management firm now holds a total of 431,961 shares of Eli Lilly and Co which is valued at $35,731,814.Eli Lilly and Co makes up approximately 0.51% of Diam Ltd.’s portfolio.
Other Hedge Funds, Including , Cadence Capital Management reduced its stake in LLY by selling 3,521 shares or 2.73% in the most recent quarter. The Hedge Fund company now holds 125,522 shares of LLY which is valued at $10,383,180. Eli Lilly and Co makes up approx 0.76% of Cadence Capital Management’s portfolio.World Asset Management Inc boosted its stake in LLY in the latest quarter, The investment management firm added 802 additional shares and now holds a total of 97,091 shares of Eli Lilly and Co which is valued at $8,031,368. Eli Lilly and Co makes up approx 0.30% of World Asset Management Inc’s portfolio.Rhenman Partners Asset Management Ab boosted its stake in LLY in the latest quarter, The investment management firm added 40,000 additional shares and now holds a total of 235,000 shares of Eli Lilly and Co which is valued at $19,439,200. Eli Lilly and Co makes up approx 3.11% of Rhenman Partners Asset Management Ab’s portfolio. Cg Asset Management sold out all of its stake in LLY during the most recent quarter. The investment firm sold 4,089 shares of LLY which is valued $341,023.Curian Capital reduced its stake in LLY by selling 112,474 shares or 63.72% in the most recent quarter. The Hedge Fund company now holds 64,037 shares of LLY which is valued at $5,101,187. Eli Lilly and Co makes up approx 0.36% of Curian Capital’s portfolio.
Eli Lilly and Co opened for trading at $81.44 and hit $81.85 on the upside on Monday, eventually ending the session at $81.6, with a gain of 0.05% or 0.04 points. The heightened volatility saw the trading volume jump to 42,27,300 shares. Company has a market cap of $90,074 M.
On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.